<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023111</url>
  </required_header>
  <id_info>
    <org_study_id>Mil GM CL-2017</org_study_id>
    <nct_id>NCT03023111</nct_id>
  </id_info>
  <brief_title>Miltefosine and GM-CSF in Cutaneous Leishmaniasis</brief_title>
  <official_title>Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universit치rio Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universit치rio Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cutaneous leishmaniasis (CL) standard treatment is done with parenteral pentavalent antimony
      (Sbv) at the dose of 15-20mg / kg per day for 20 days. However, therapeutic failure has been
      described in up to 50% of patients, and the long period of 60 to 90 days required for healing
      of the ulcerated lesion indicate the need for alternative drugs. Currently the alternatives
      include other parenteral drugs such as pentamidine and amphotericin B, whose use is limited
      either by toxicity or because, as with Sbv, the parenteral route hinders adherence and
      regularity of treatment in the rural area. Recent studies by our group indicate that oral
      miltefosine is the most effective drug for the treatment of patients with CL caused by L.
      (V.) guyanensis and L. (V.) braziliensis in Brazil, with a cure rate of 71.4% and 75%
      respectively. CL pathogenesis is associated with intense inflammatory infiltrate and tissue
      damage. Previous trials associating GM-CSF to Sbv improved the cure rate of CL caused by L.
      (V.) braziliensis. The objective of this trial is to evaluate the therapeutic response to the
      use of miltefosine associated to GM-CSF in the treatment of CL caused by L. (V.) braziliensis
      in an endemic region in Bahia and Cear치, and by L. (V.) guyanensis in the Amazon region.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final cure rate or complete cicatrization of the ulcer</measure>
    <time_frame>6 months after the end of treatment</time_frame>
    <description>All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients. Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure rate or initial cicatrization of the ulcer</measure>
    <time_frame>2 months after the end of treatment</time_frame>
    <description>All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients. Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time</measure>
    <time_frame>Up to 2 months after the end of treatment</time_frame>
    <description>Time (in days) to achieve complete cicatrization will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and laboratory adverse events</measure>
    <time_frame>During treatment and through study completion, an average of 1 year</time_frame>
    <description>Clinical and laboratory adverse events will be recorded and graded according to the Common Terminology Criteria for Adverse Event (CTCAE) of the National Cancer Institute</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Sbv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meglumine antimoniate (Glucantime):
Dosage: 20 mg / kg / day, intravenously, during 20 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miltefosine plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miltefosine plus GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sbv</intervention_name>
    <description>Standard treatment for CL, parenteral drug used during 20 days.</description>
    <arm_group_label>Sbv</arm_group_label>
    <other_name>Glucantime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine plus placebo</intervention_name>
    <description>Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.</description>
    <arm_group_label>Miltefosine plus placebo</arm_group_label>
    <other_name>Impavido plus placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine plus GM-CSF</intervention_name>
    <description>Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.</description>
    <arm_group_label>Miltefosine plus GM-CSF</arm_group_label>
    <other_name>Impavido plus GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Untreated ulcerative cutaneous leishmaniasis, with laboratory diagnosis obtained
             through at least one of the following tests: direct examination of the lesion,
             positive culture or PCR for Leishmania.

          2. Age: 18 to 65 years;

          3. Sex: male and female patients;

          4. Presence of at least 1 ulcerated lesion at any location;

          5. Presence of a maximum of 3 ulcerated lesions;

          6. Diameter of lesions varying between 1 and 5 cm;

          7. Clinical evolution of the disease of not less than 1 month and not more than 3 months.

        Exclusion Criteria:

          1. Evidence of severe underlying disease (cardiac, renal, hepatic, pulmonary) or
             malignant disease;

          2. Patients with immunodeficiency or HIV carriers;

          3. Serious protein and / or caloric malnutrition;

          4. Active and uncontrolled infectious-contagious disease such as tuberculosis, leprosy,
             systemic fungal disease (histoplasmosis, paracoccidioidomycosis) or any other similar
             condition;

          5. Women who are pregnant or breastfeeding;

          6. Allergy to Sbv or miltefosine;

          7. Previous treatment for leishmaniasis;

          8. Lack of capacity or willingness to provide informed consent (patient and / or parent /
             legal representative); Absence of availability for the visits or to comply with the
             study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo RL Machado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edgar M Carvalho, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Fernandes Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manoel Barral Neto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Fernandes Figueira</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerson Penna, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Fernandes Figueira</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulo RL Machado, MD, PhD</last_name>
    <phone>55-71-32377353</phone>
    <email>prlmachado@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edgar M Carvalho, MD, PhD</last_name>
    <phone>55-71-32377353</phone>
    <email>edgar@ufba.br</email>
  </overall_contact_backup>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universit치rio Professor Edgard Santos</investigator_affiliation>
    <investigator_full_name>Paulo Roberto Lima Machado</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cutaneous leishmaniasis</keyword>
  <keyword>miltefosine</keyword>
  <keyword>cytokines</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

